Trial Profile
A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jan 2021
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Allergic asthma
- Focus Registrational; Therapeutic Use
- Acronyms ARIA
- Sponsors AstraZeneca
- 30 Oct 2019 Status changed from active, no longer recruiting to completed.
- 08 May 2019 Planned End Date changed from 12 Sep 2019 to 23 Oct 2019.
- 08 May 2019 Planned primary completion date changed from 12 Sep 2019 to 23 Oct 2019.